Mazdutide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A dual GLP-1 and glucagon receptor agonist for weight loss and blood sugar control. Human evidence for weight loss and glucose control is strong, though long-term safety data are limited and liver benefit evidence is weak. Gastrointestinal side effects are common, heart rate can rise, and hypoglycemia is a risk at higher doses, while thyroid tumor risk remains theoretical. It is not an approved drug in the US; supply is unregulated research-grade product.
Read Full recordStudied uses & evidence
Studied uses(7)
Significant Weight Loss
HighPhase 3 trial showed up to 14% body weight loss at 48 weeks versus placebo.
Glycemic Control
HighHuman RCTs show significant HbA1c reduction; approved in China for type 2 diabetes.
Dual Mechanism of Action
MediumGLP-1 effects proven in humans; added energy-expenditure benefit is mechanism-based, not directly measured.
Evidence limits
- Evidence Level
- Strong
Supported by multiple Phase 1b, Phase 2, and Phase 3 randomized controlled trials, two systematic reviews/meta-analyses, and regulatory approval in China. The GLORY-1 Phase 3 trial (NEJM, 2025) provided pivotal evidence for weight management. A Phase 2 trial in type 2 diabetes (Diabetes Care, 2023) demonstrated glycemic and weight benefits. Meta-analyses (Frontiers in Endocrinology, 2024; Diabetes Obesity & Metabolism, 2026) confirm consistent efficacy across trials. US Phase 2 results were published in August 2026.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Personal/family history of MTC
AbsoluteDual GLP-1/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.
History of pancreatitis
HighGLP-1 class effect. Monitor for pancreatitis signs and symptoms.
Severe gastroparesis
HighGLP-1 component slows gastric emptying significantly.
General cautions
Pregnancy
AbsoluteInvestigational compound. No reproductive safety data.
Risk summary(9)
Risks = level of concern: High · Moderate · Low · Theoretical
Gastrointestinal adverse events: diarrhea (28-41%), nausea (21-25%), vomiting (12-16%), decreased appetite (27-31%), abdominal distension (4-12%)
HighHeart rate increase: 5-17 bpm elevation above baseline observed across doses
ModerateHypoglycemia risk: up to 16% at higher doses, especially when used with other antidiabetic agents; severe hypoglycemia rare
ModerateInjection site reactions: 4-6% incidence
LowImmunogenicity: treatment-induced anti-mazdutide antibodies detected in 10-20% of participants, though no impact on efficacy or safety observed
LowPotential thyroid C-cell effects: class concern for GLP-1 receptor agonists; no C-cell hyperplasia or thyroid tumors observed in trials but long-term surveillance needed
TheoreticalCardiovascular effects: supraventricular extrasystoles and sinus tachycardia observed in small percentages; all asymptomatic and transient
LowLimited long-term safety data: most evidence from trials of 20-48 weeks duration; post-marketing surveillance ongoing in China
ModerateWeight regain upon discontinuation: as with other GLP-1 agonists, weight regain expected after stopping treatment
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.